alexa Targeting Stem Cell Protein BMI1; A Potential Therapeut
ISSN: 2157-7633

Journal of Stem Cell Research & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Targeting Stem Cell Protein BMI1; A Potential Therapeutic Approach for Prostate Cancer Therapy

Firdous H Beigh1, Nidda Syeed2, Mohsin Maqbool3 and Rita Singh Majumdhar1*

1Departments of Biotechnology, Sharda University, Greater Noida, India

2Department of Biotechnology, JMI, New Delhi, India

3Department of Medical Oncology, IRCH, AIIMS, New Delhi, India

Corresponding Author:
Prof. Rita Sing Mujamdhar
Prof & Head Department of Biotechnology
Sharda University, India
Tel: 0120 457 0000
E-mail: [email protected]

Received Date: May 01, 2017; Accepted Date: May 11, 2017; Published Date: May 17, 2017

Citation: Beigh FH, Syeed N, Maqbool M, Majumdhar RS (2017) Targeting Stem Cell Protein BMI1; A Potential Therapeutic Approach for Prostate Cancer Therapy. J Stem Cell Res Ther 7:388. doi: 10.4172/2157-7633.1000388

Copyright: © 2017 Beigh FH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Prostate cancer (CaP) is considered as a vexing challenge for clinical management because of its resistance to the conventional therapies, resulting in most deaths from this disease. The current treatment options including castration shows minimal effect, as most of the patients develop resistance and relapse of more aggressive Castration Resistant Prostate Cancer (CRPC). BMI1 (B cell-specific Moloney murine leukemia virus integration site 1), an oncogenic member of the polycomb group gene family and a transcriptional repressor has emerged as a key regulator in numerous processes including proliferation, differentiation, senescence, and stem cell renewal. Accumulating evidences have also revealed a relationship between BMI1 expression and the clinical grade/stage, therapy response, and survival outcome in most human malignancies, including Prostate cancer. Therefore, in this review, we provide the significant evidences suggesting the potential of BMI1 as a therapeutic target in the management of prostate cancer.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version